Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab combined with anlotinib for refractory small cell lung cancer after failure of first-line platinum chemotherapy
ChiCTR2000033793Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000033793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033793.